Island Pharmaceuticals Ltd Gains Singapore Patent for ISLA 101
Key points
- Singapore patent for ISLA 101 covers treatment of flavivirus and Chikungunya
- Patent strengthens Island's intellectual property portfolio
- Patent extends until 2034, enhancing commercial opportunities
Full summary
Island Pharmaceuticals Ltd announced that the Intellectual Property Office of Singapore has granted a patent for the use of ISLA 101 to treat flavivirus, including Dengue, and Chikungunya virus infections. The patent, titled 'Method of Viral Inhibition', covers the use of ISLA 101 as a standalone antiviral therapy and extends until 16 April 2034. This patent strengthens Island's intellectual property portfolio, enhancing its commercial and partnering position in the Asia-Pacific region, where Dengue and other mosquito-borne viral diseases remain endemic.
Outlook
The patent grant further reinforces Island's commercial and partnering position as it advances ISLA-101 for Dengue and other flavivirus indications.
Summary generated by a large language model. Please interpret with care.